These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32929230)

  • 1. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
    Deacon CF
    Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
    Panda SP
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Campos C; Unger J
    Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
    Ribeiro-Silva JC; Marques VB; Dos Santos L
    Am J Physiol Cell Physiol; 2023 Oct; 325(4):C972-C980. PubMed ID: 37642237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
    Yin R; Xu Y; Wang X; Yang L; Zhao D
    Molecules; 2022 May; 27(10):. PubMed ID: 35630534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.
    Zakaria EM; Tawfeek WM; Hassanin MH; Hassaballah MY
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1357-1372. PubMed ID: 35945358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
    Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
    Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: A propensity score-matched cohort study.
    Cheung JTK; Yang A; Wu H; Lau ESH; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
    Diabetes Metab Res Rev; 2024 Jan; 40(1):e3711. PubMed ID: 37634071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
    Roberto G; Barone-Adesi F; Giorgianni F; Pizzimenti V; Ferrajolo C; Tari M; Bartolini C; Da Cas R; Maggini M; Spila-Alegiani S; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
    BMC Endocr Disord; 2019 Feb; 19(1):18. PubMed ID: 30732592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.